Clinical Trials Logo

Neuralgia clinical trials

View clinical trials related to Neuralgia.

Filter by:

NCT ID: NCT05009394 Recruiting - Phantom Limb Pain Clinical Trials

Surgical Treatments for Postamputation Pain

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.

NCT ID: NCT05005026 Recruiting - Clinical trials for Spinal Cord Injuries

Virtual Walking Intervention for Neuropathic Pain in Spinal Cord Injury

VRWalk
Start date: November 23, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with chronic spinal cord injury.

NCT ID: NCT04996199 Recruiting - Clinical trials for Trigeminal Neuralgia

Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial

Start date: September 18, 2021
Phase: Phase 4
Study type: Interventional

Trigeminal neuralgia is a neuropathic facial pain condition, characterized by unilateral paroxysmal pain which can be described as stabbing or electric shock like, in the distribution of one or more divisions of trigeminal nerve which is triggered by innocuous stimuli. The attack is provoked by touching or stimulating these trigger zones. There are various pharmacological drugs present for the treatment of trigeminal neuralgia. Carbamazepine and oxcarbazepine are the first-choice drugs for the treatment of TN. Other drugs include lamotrigine , baclofen , gabapentin, antidepressants , eslicarbazepine , sumatriptan & vixitrigine. The carbamazepine is first choice of drug which has serious side effects including dizziness, memory loss, sleppiness, aplastic anaemia. Oxcarbazepine has similar mechanism of action and found to have lesser adverse events when used in various neuralgias in the place of carbamazepine. But there is still lack of evidence to prove that oxcarbazepine can be used as monotherapy in TN patients.

NCT ID: NCT04967664 Recruiting - Clinical trials for Post Surgical Neuropathic Pain

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Start date: July 13, 2021
Phase: Phase 3
Study type: Interventional

This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).

NCT ID: NCT04936646 Recruiting - Clinical trials for Chronic Neuropathic Pain

Study of rTMS Analgesic Effect in Chronic Neuropathic Pain,

NEUROSTIM
Start date: July 16, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the analgesic effectiveness of three modes of repetitive Transcranial Magnetic Stimulation (rTMS) in chronic neuropathic pain: - Classical rTMS stimulation - Deeper rTMS stimulation - Sham rTMS stimulation

NCT ID: NCT04930887 Recruiting - Migraine Clinical Trials

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).

NCT ID: NCT04917796 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Start date: May 21, 2021
Phase: Phase 3
Study type: Interventional

Electroacupuncture (referred to as EA) may be an effective treatment for Chemotherapy-Induced Peripheral Neuropathy/CIPN pain. Acupuncture is a medical technique that involves insertion of very thin needles into specific areas on the body with the goal of promoting health and well-being. EA involves adding a very small amount of electricity through the acupuncture needles (electrical stimulation). Researchers have found that EA can increase the effects of regular acupuncture, and it is particularly helpful for treating different kinds of pain. The purpose of this study is to learn if EA can improve CIPN pain in cancer survivors, and if it is effective against other CIPN-related symptoms.

NCT ID: NCT04917107 Recruiting - Clinical trials for Spinal Cord Injuries

CREATION: A Clinical Trial of Qigong for Neuropathic Pain Relief in Adults With Spinal Cord Injury

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Between 39-67% of the 294,000 Americans who have a SCI suffer from long-term debilitating neuropathic pain, interfering with rehabilitation, general activity, mobility, mood, sleep, and quality of life. Pain can hinder any potential for functional improvement that could be obtained during rehabilitation. Yet, neuropathic pain is refractory to many treatments. Current interventions, such as medications and physical therapy, result in less than 50% reduction in pain for only about one third of the people trying them, calling for new treatment options. Qigong, a mind and body approach that incorporates gentle body movements, paired with a focus on breathing and body awareness to promote health and wellness, could reduce SCI-related neuropathic pain. If the hypothesis is supported, the resulting work could be transformative in demonstrating a potentially effective therapy for civilians, military Service members, and Veterans with SCI and neuropathic pain. The following provides the scientific basis for this hypothesis and establishes the rationale for this approach. This study also includes an optional, remote, quasi-experimental substudy, in which all participants will receive Qigong for 12 weeks, followed by 6 weeks followup.

NCT ID: NCT04911569 Recruiting - Neuropathic Pain Clinical Trials

Cryoneurolysis for Cutaneous Neuropathic Pain

Start date: June 7, 2021
Phase: N/A
Study type: Interventional

Feasibility study with 25 patients investigating the effect of cryoneurolysis on persistent cutaneous neuropathic pain after surgery and trauma. All patients receive active treatment (cryoneurolysis). The study design is unblinded, non-randomized, non-controlled.

NCT ID: NCT04909593 Recruiting - Chronic Pain Clinical Trials

Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial

AIM
Start date: May 24, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the feasibility of using information extracted from physiologic signals to automatically adjust stimulation in patients undergoing Spinal Cord Stimulation (SCS).